BIO-Europe Spring 2015
Biotech-Hotspot
North Rhine-Westphalia
Paris, France
March 9 – 11, 2015
Hall 5, Stand 44
Dear visitors and exhibitors,

In 2015, BIO.NRW and NRW.International attend the BIO-Europe Spring again together with a joint pavilion. Eight highly innovative exhibitors present the diversity and innovative potential of the biotech scene in North Rhine-Westphalia (NRW).

North Rhine-Westphalia with its 87 dedicated biotech companies (according to OECD) is home to the fastest growing Biotechscene in Germany; 4 new biotech companies in 2013, 7 new companies in 2012 and six in 2011. NRW is the leading location in the country with regard to number of people employed (3,900) by the industry as well as the turnover (44 % of the German Biotech turnover) generated by its dedicated biotech companies.

Even though being a rather small overall business sector according to the mere statistics, biotechnological solutions and products provide invaluable answers to our society’s challenges, like healthy living and ageing, limited energy supplies or the climate change and thus create an enormous economic impact.

Get a feel for innovation and investment opportunities in the heart of Europe. We are looking forward to seeing you at our pavilion in hall A5.2 stand 44. We wish all exhibitors, congress participants and visitors successful days at BIO-Europe Spring 2015.

Dr. Bernward Garthoff  
Chair of Cluster Biotechnology

Almut Schmitz  
CEO NRW.International North Rhine-Westphalia
Floor Plan of the
North Rhine-Westphalian Pavilion

Content

Foreword 1
Floor Plan of the
North Rhine-Westphalian Pavilion 2
Exhibitors
BIBITEC GmbH 4
BIO.NRW Cluster Biotechnology
North Rhine-Westphalia 5
CEVEC Pharmaceuticals GmbH 6
Chimera Biotec GmbH 7
CRS Clinical Research Services 8
Grünenthal – Innovative Medicines Unit,
Grunenthal GmbH 9
MLM Medical Labs GmbH 10
NRW.International GmbH 11
PS Biotech GmbH 12
vivo Science GmbH 13
Notes 14

Organisation/Sponsors 17
BIBITEC Gesellschaft für Prozessentwicklung mbH, member of the NORDMARK Group, has longtime experience in process development based on mammalian cell culture as well as producing the drug substance up to 200 liter scale for clinical trials. A general, valid GMP-certificate and a general production license for APIs are available.

In this context BIBITEC developed the process and established the production of the API of EPO zeta (the second approved EPO biosimilar) to be used in clinical trials. Nowadays the API production for market supply is established on NORDMARK’s production site.

Together, BIBITEC, NORDMARK and our validated partners are able to provide all activities from “gene to product” including cell line and process development, GMP production, fill-and-finish and analytics. The company objective is the production of APIs or drug products for market purposes.

North Rhine-Westphalia’s biotechnology cluster BIO.NRW is a central catalyst for the sustainable development of the state’s biotech sector. It activates cooperation between business, research, investors and policy-makers. The cluster also promotes the strengths and achievements of biotechnology in the state: industrial biotechnology and pharmaceutical biotechnology. BIO.NRW is part of an initiative by North Rhine-Westphalia’s (NRW) state government, which aims at making NRW the number one state for innovation. It has therefore established 16 technology clusters to systematically improve NRW’s strengths and talents in established industries and up-and-coming fields like biotechnology. Goal of the “Excellence NRW” cluster strategy is to create a favourable climate for innovation, as that is the best way to sustain the competitive edge and stimulate growth and employment in the companies that call the state their home.

Services
- Technology Transfer
- Support of Biotech Companies, esp. SME
- Support of Biotech Start-ups, Coaching & Financing
- National and International Fairs, Exhibitions, and Conferences
- Analysis of biotechnology in North Rhine-Westphalia for location data
- Marketing & PR for the biotech state of NRW
- Promotion of young academics

BIBITEC GmbH
Dr. Jörg Stute
Meisenstraße 96
D-33607 Bielefeld
Phone: +49 521/106-6326
joerg.stute@bibitec.de
www.bibitec.de

BIO.NRW Cluster Biotechnology
North Rhine-Westphalia
Dr. Bernward Garthoff
Merowingerplatz 1
D-40225 Düsseldorf
Phone: +49 211/385469-9201
b.garthoff@bio.nrw.de
www.bio.nrw.de
CEVEC is a global solution provider for the production of biopharmaceuticals and vaccines using a unique human cell expression system. CAP and CAP-T cells are based on specific, amniocyte-derived human cell lines and are designed for stable and transient biopharmaceutical protein and virus/vaccine production. The cell lines exhibit a broad susceptibility for various virus species and excellent titers have e.g. been observed (among others) for RSV, CMV and gene therapeutic vectors like AV, LV or AAV.

Next to outlicensing the technology to international pharma and biotech companies, CEVEC is your contract manufacturer of choice for cGMP production in CAP Cells.

CAP-derived clinical material can be provided for phase I – II studies and we produce your desired protein, vaccine, virus or gene therapy vector at extraordinary pace and competitive pricing through our CAP CMO Joint Venture with Genibet in Lisbon/Portugal.

Chimera Biotec’s proprietary Imperacer® technology pairs the specificity of antibodies with the sensitivity of DNA analysis.

Take advantage of Chimera Biotecs over 15 years in-depth experience as specialty CRO for immunoassays beyond the scope of what is usually considered feasible.

- Ultra sensitive immunoassays
- Broad assay range
- Very low sample requirement
- No significant hook effect

Exponential signal amplification allows flexible conversion of assay sensitivity towards study specifics.

Chimera Biotec offers:

- Ultra Sensitive Bioanalysis: Wherever traditional ELISA support fails
- Assay Development: Custom designed and optimized for your study requirements
- Method Validation: According to regulatory guidance and industry whitepapers
- Broad Application: Specialty PK, Biomarker, Microsampling, Immunogenicity

CEVEC Pharmaceuticals GmbH
Irina Lutz
Gottfried-Hagen-Straße 62
D-51105 Köln
Phone: +49 221/46020823
lutz@cevec.com
www.cevec.com

Chimera Biotec GmbH
Dr. Beena Punnamoottil
Emil-Figge-Straße 76A
D-44227 Dortmund
Phone: +49 231/9742840
info@chimera-biotec.com
www.chimera-biotec.com
6 CPUs, 300 beds and a 3 decades’ track record of more than two thousand completed trials make CRS Clinical Research Services the leading Early Phase CRO in Europe and your partner of choice.

Besides the standard Early Phase studies in healthy volunteers, a substantial part of CRS’s business is the conduct of patient driven trials such as proof-of-concept trials as well as multicenter trials in phase II – IV. CRS offers a full-service package including consultancy, project management, clinical conduct, QA/QC, IMP management, data management and medical writing. All CRS’s clinical units are located in metropolitan areas, one being based in a university hospital. This ensures fast recruitment and the availability of a large pool of both volunteers and patients.

Due to the long-standing history, CRS offers a broad expertise in various therapeutic areas. CRS has been audited by numerous sponsors and has been inspected by national and international authorities. Clients from pharmaceutical, biotech and medical device companies of all sizes profit from CRS’s broad expertise in clinical research.

The Innovative Medicines Unit (IMU) at Grüenthal is a new initiative that synergizes the innovative and entrepreneurial practices of biotech and the established capabilities of a successful mid-sized pharma company.

The IMU is founded on an entrepreneurial and networked approach to R&D. It identifies new opportunities from the external innovation community, in late-stage discovery or early clinical development, and attains their commercial and medical value. This is achieved through a culture of innovation, risk-sharing and entrepreneurship. The IMU is the meeting point for Grüenthal with the external community, through its creation of “clusters” of licensed assets and strategic partnerships which share risk and reward. It has a focus on therapeutic niches that include opportunities outside of Grüenthal’s current core expertise.

The IMU works alongside existing partnership and alliance activities at Grüenthal. In so doing, it will enhance Grüenthal’s position as the partner of choice and allow it to meet the significant medical challenges of the future.

For more information, please contact Simon Read, VP, Head of Innovative Medicines Unit at simon.read@grunenthal.com or Darcey Black, External Innovation Lead at Darcey.black@grunenthal.com
MLM Medical Labs is a CAP- and DIN EN ISO 15189-accredited, GLP-certified and CLIA-registered central and specialty lab that is dedicated exclusively to clinical trials phase I to IV. MLM was founded in 1993 and its staff of 30 employees assist in 70 – 80 clinical studies simultaneously.

MLM offers the entire portfolio of service elements necessary to laboratory support clinical trials:
- Development and validation of special analytical methods
- Global supply of study-specific sampling kits
- World-wide sample logistics
- Clinical chemistry, hematology, serology and urinalysis
- Biomarker assays including multiplex panels
- Long term storage of samples at – 30°C and – 80°C
- Web Access – mlm online®

MLMs clients are renowned CROs, biotech and global pharmaceutical companies as well as universities based in Europe, Asia and USA. MLMs services are offered 365 days a year.

We create a reliable partnership with our clients that represent:
- Scientific Excellence
- Customized Solutions
- Personal Accountability

NRW.International – Partner for worldwide business

NRW.International is the organisation in charge of export promotion in the federal state of North Rhine-Westphalia.

NRW.International has been set up as a public private partnership between the federal government of North Rhine-Westphalia and the regional Chambers of Skilled Crafts, small and medium sized enterprises, the regional Chambers of Industry and Commerce and the development bank of North Rhine-Westphalia. It is responsible for the organisation of joint trade fair presentations abroad, the coordination and support of international trade delegations from North Rhine-Westphalia to foreign countries and the pooling and editing of foreign trade information relevant for companies from the region. NRW.International coordinates these activities between intermediary organizations and the government of North Rhine-Westphalia in order to provide excellent services and political backing by the regional representatives to the business community.

MLM Medical Labs GmbH
Dr. Katja Neuer
Dohrweg 63
D-41066 Mönchengladbach
Phone: +49 2161/4642-102
kneuer@mlm-labs.com
www.mlm-labs.com

NRW.International GmbH
Bety Chu
Völklinger Straße 4
D-40219 Düsseldorf
Phone: +49 211/71067-10
bety.chu@nrw-international.de
www.nrw-international.de
PS Biotech GmbH is based in Aachen close to the RWTH Aachen. The company is developing, producing and selling polymer release systems for biotechnological applications.

PS Biotech’s products offer a novel and unique solution for fed-batch feeding of microorganisms in microliter scale.

In “Feed Plate®” nutrients are being released from a special polymer matrix, immobilized at the bottom of a microtiter plate through diffusion.

Feed Plate® enables the generation of precise, process near conclusions during screenings, resulting in an optimized scale-up process.

Synchronization of physiological conditions in screening and production leads to reliable results of unknown quality and thus immensely increases the efficiency within the scope of screening and application in production.

to safety and potency tests for vaccines, vivo Science provides a wide range of invivo tests in rodents. You need a special immune modulating test (ADA, ASA, DTH) or immune histochemical detection? A tissue cross reactivity study? Just ask. vivo Science is also able to include any immunological test into standard toxicity and related studies.

vivo Science is a privately held CRO for pre-clinical studies. Its focus is on toxicology, potency and influence on the immune system of substances. Generally vivo Science services includes tests for the following market segments: Pharmaceuticals, esp. biologics, chemicals, medical devices, vaccines and viral safety (PTC1993). From the testing of immunotoxicity (ICH-S8) and immunogenicity (ICH-S6) of new drug candidates, over repeated dose toxicity studies (OECD 407, 408 etc., EMA, FDA) and biocompatibility test (cytotoxicity, sensitization, irritation etc.) to safety and potency tests for vaccines, vivo Science provides a wide range of invivo tests in rodents. You need a special immune modulating test (ADA, ASA, DTH) or immune histochemical detection? A tissue cross reactivity study? Just ask. vivo Science is also able to include any immunological test into standard toxicity and related studies.

vivo Science GmbH
Gerhard Lewandovski
Fabrikstraße 3
D-48599 Gronau
Phone: +49 2562/8170-28
gerhard.lewandovski@vivoscience.de
www.vivoscience.de

PS Biotech GmbH
Kristina Bruellhoff
Kackertstraße 4
D-52072 Aachen
Phone: +49 2418/94644110
info@psbiotech.com
www.psbiotech.com